The trademark application EUTULA was filed by AbbVie Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on October 27, 2022, and it was registered by office on February 3, 2023 without any oppositions.
The application was filed in English (French was selected as the second language).
Goods And Services
The mark was filed in class 5 with Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders.